Composite probiotics and use thereof

Abstract

The present disclosure relates to the field of microbial technology, and discloses a composite probiotics and the use thereof. The composite probiotics in the present disclosure is consisted of Bifidobacterium adolescentis CCFM8630, Lactobacillus reuteri CCFM8631, Lactobacillus rhamnosus CCFM1044 and Lactobacillus casei CCFM711, whose effect of alleviating metabolic syndrome is significantly better than that of CCFM8630 or CCFM8631 alone or combination of the two, especially in aspects of lowering contents of serum low density lipoprotein, total cholesterol, and liver triglyceride and contents of serum alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase and IFN-γ, and increasing contents of liver glutathione and superoxide dismutase, etc. The extent of decrease or increase is increased by 7.91% to 837.31% compared with the formulations of CCFM8630 or CCFM8631 alone or combination of the two probiotics. The combination of the four probiotics can achieve a significant synergistic effect.

Dependencies are inferred from the claim text.